Available information on the free release of genetically modified insects into the wild is highly restrictedFebruary 02, 2012
While genetically modified plants have already been introduced into the wild on a large scale in some parts of the world, the release of genetically modified animals is still at a relatively early stage. A team of scientists from the Max Planck Institute for Evolutionary Biology in Plön, Germany has now published a study examining the free release of genetically modified insects in Malaysia, USA, and Cayman Islands. Their findings suggest deficits in the scientific quality of regulatory documents and a general absence of accurate experimental descriptions available to the public before releases start. The researchers call for clear and accurate descriptions of releases to be very widely circulated before insects are released in a trial - particularly if mosquito species that bite humans are involved. They also provide an innovative checklist to assist journalists and the public in assessing the scientific credibility of regulatory release authorizations.
Genetically modified insects are being developed with a view to suppress insect populations of the same species which spread human diseases, such as malaria and Dengue Fever, or that are agricultural pests destroying crops. The first generation of "designer insects" have been engineered to be fluorescently marked, to be sterile to varying degrees, or both. These insects are released experimentally to develop species-specific and chemical-free ways to reduce the size of insect pest populations.
A team of researchers from the Max Planck Institute for Evolutionary Biology have now investigated the regulatory history of genetically modified insects, with a particular focus on the pre-release information available to the public in the first three countries permitting free releases: the Cayman Islands (mosquitoes, 2009-?), Malaysia (mosquitoes, 2010-2011), and the USA (moths, 2001-2011). The study centres on the US regulatory experience, which is currently being promoted as a global regulatory model for genetically modified insects.
Global deficits in transparency and public oversight
The world's first environmental impact statement on genetically altered insects was produced by US authorities in 2008 and has since then been used as a basis for approval of subsequent experiments around the world. The scientists raise some doubts about the scientific value of this environmental impact statement: for example the majority of novel transgenic approaches it endorses are based on just two laboratory studies out of approximately 170 scientific studies cited. These two studies focus only one of the four species covered by the document. Apparently, such deficits do not only apply to the US. "We noted that public access to scientific information is highly restricted throughout the world, particularly information made available before releases start", says Guy Reeves from the Max Planck Institute for Evolutionary Biology.
The Cayman Islands was in 2009 the site of the first free release of genetically modified mosquitoes. There were, however, some doubts about the relative strength of the legal safeguards that existed. The Cayman Islands had no enacted legislation specifically mentioning the release or transportation of living genetically modified organisms. In 2009 only 21 of the world's 191 countries also had not updated their existing environmental protection or animal control laws to specifically regulate living genetically modified organisms. While the Cayman Islands is a British overseas territory and consequently not a sovereign state, it is noteworthy that none of these 21 countries is thought to have approved any release of a living genetically modified organism.
The first and most obvious question of people living in the release sites of the genetically modified mosquitoes (OX513a) in the Cayman Islands, Malaysia, and Brazil is whether humans can be bitten by genetically modified mosquitoes. In public information available in the Cayman Islands and Malaysian trials, this obvious question is either conspicuously ignored or it is implied that the there is no biting risk, 'as only male mosquitoes are released and they cannot bite'. However, it is clearly detailed by the Max Planck scientists, that it is probable that transgenic daughters of the released males will bite humans. This is because the released males are more accurately described as partially sterile males, rather than the commonly used term sterile males - or most recently 'sterile' males.
A potential concern about the effects of humans being bitten by these genetically modified females is discussed. The context of this discussion is not to suggest that this technology is inherently dangerous. It is to highlight the fact that public confidence in regulators will be eroded, if written discussion of obvious and scientifically plausible concerns is conspicuously absent from all written documents. As far as the authors are aware there are no publically available documents that scientifically consider possible human health impacts of being bitten by transgenic females (beyond unsubstantiated statements in the general media).
Community engagement and consent requires transparency
The general lack of accurate information available before starting releases is problematic. This is because community engagement fundamentally requires that release descriptions be widely circulated before releases start. The need for high-quality community engagement, particularly in early releases, has repeatedly been argued as essential by expert scientists. "It is rather uncontroversial to state that in the absence of meaningful and accurate descriptions being made widely available, community engagement cannot credibly be said to have occurred", says Reeves.
If those that conducted the trials cannot produce pre-release written descriptions, then they need to explicitly state why meaningful community engagement and consent might not be necessary for experimental releases into towns and cities. Individuals providing justifications based on the pressing humanitarian need to rush development of this technology, must also explain why the same argument cannot be applied to clinical trials of vaccines.
Giving genetically modified insects a fair trial
Large numbers of genetically modified mosquitoes are currently being released in Brazil. Further releases are reportedly under evaluation in various countries, including France, Guatemala, India, Mexico, Panama, Philippines, Singapore, Thailand, Vietnam and the UK. Proposed experimental releases are for both human health purposes and to control agricultural pests.
Given the enormous human burden of diseases like dengue fever and crop loss from insect attack, it is important that new control techniques are developed. Field trials are an essential step in the evaluation process. "However, we need an informed public to ensure that experimental testing of this potentially valuable technology can be given a fair chance and that testing does not needlessly provoke public mistrust", says Reeves. Avoiding the kind of questionable practices which characterized the commercial development of genetically modified plant is likely to be important.
Related Genetically Modified Current Events and Genetically Modified News Articles
Disruptions to embryonic reprogramming alter adult mouse behavior
Right after fertilization, embryos at the earliest stages of development tell their genes: "Forget what it was like in the sperm or egg where you came from."
UAB researchers find protein that improves mobility after spinal cord injuries
Spinal cord injuries cause severe functional disabilities in those who sustain them, including paraplegia or tetraplegia, depending on the scale of the injury.
Exact pol(e) position -- precisely where the polymerase is changed
Scientists at the Helmholtz Zentrum München, working with colleagues from the Ludwig-Maximilians-Universität München, have developed a method for the thorough analysis of protein modifications.
Certain herpes viruses can infect human neurons
For years, researchers have noted a tantalizing link between some neurologic conditions and certain species of the herpes virus. In patients with Alzheimer's disease, multiple sclerosis, and cerebellar ataxia, among other neuropathies, the cerebrospinal fluid teems with Epstein-Barr virus (EBV).
Magnesium ions show promise in slowing progression of Alzheimer's disease in mice
New research published in the December 2015 issue of The FASEB Journal, shows that in mouse models of the disease oral administration of magnesium-L-threonate (MgT) alleviated cognitive decline by suppressing the Aβ deposition in amyloid plaques in an APH-1α/1β-dependent manner.
Shining light on microbial growth and death inside our guts
For the first time, scientists can accurately measure population growth rates of the microbes that live inside mammalian gastrointestinal tracts, according to a new method reported in Nature Communications by a team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School.
Genetic modification shows promise for preventing hereditary hearing loss
A mitochondrial defect is responsible for a type of human hereditary deafness that worsens over time and can lead to profound hearing loss.
Fighting citrus greening with vibrating orange groves
When a male Asian Citrus Psyllid is looking for a mate, he situates himself on a twig, buzzes his wings to send vibrations along adjacent leaves and branches, and listens for a female's response call. If the call comes, he travels in her direction, the abbreviated insect version of courtship ensues, and two to seven weeks later, scores of psyllids nymphs emerge from their eggs, feed on phloem sap, and mature into adults who head out into the world, ravaging untold numbers of citrus trees in the process.
Snake venom helps hydrogels stop the bleeding
A nanofiber hydrogel infused with snake venom may be the best material to stop bleeding quickly, according to Rice University scientists.
Synthetic biology applications face unclear path to market
The pathway to market for new products utilizing synthetic biology can be difficult to navigate, posing a challenge for companies in their efforts to commercialize new ideas, while the novelty posed by some of these products can make it difficult for regulatory agencies to evaluate risks, according to a new report from the Synthetic Biology Project.
More Genetically Modified Current Events and Genetically Modified News Articles